ClinicalTrials.gg
RecruitingNCT07428707Updated Nov 17, 2026

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

An Early Phase 1 interventional study of Pirtobrutinib in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by National Heart, Lung, and Blood Institute (NHLBI). Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
19th of 23
30 · median 87
Started
2026
with 4 others
Phase 1
Only one
of the 23
Primary completion
2030-02
later than 12 of 18 live
Registered
21st of 23
by date
Lead sponsor
1 of 23
National Heart, Lung, and Blood Institute (NHLBI)

Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 19th largest by planned enrollment, is one of 5 that started in 2026, is the only one in phase 1, reaches primary completion later than 12 of the 18 other live ones, and was the 21st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

Background:

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. Pirtobrutinib is a drug approved to treat CLL and SLL after 2 previous treatments. Researchers want to know how this drug affects the immune system in those who have not yet started other treatments for CLL or SLL.

Objective:

To test pirtobrutinib as a first-line treatment for CLL or SLL.

Eligibility:

People aged 18 years and older with untreated CLL or SLL.

Design:

Participants will be screened. They will have a physical exam with blood tests. They will have imaging scans and tests of their heart function. They will have a lymph node biopsy: A large needle will be inserted into a lymph node to collect a small piece of tissue.

Pirtobrutinib is a tablet taken by mouth. Participants will take 2 to 4 tablets daily in 4-week cycles.

Participants will have clinic visits once every 4 weeks for the first 3 months. Then they will be seen once every 3 months.

Imaging scans, lymph node biopsy, and other tests will be repeated at various study visits.

A bone marrow biopsy (collection of soft tissue from inside a bone) may be done if there is no evidence of disease after 1 year of treatment with the study drug.

Participants may opt to have cancer and immune cells collected from their blood. The cells will be used for research.

Participants will have a clinic visit 1 month after their last dose of the study drug. Then they will have follow-up visits or phone calls every 6 to 12 months....

Read the detailed description

Study Description: This is a pilot study of pirtobrutinib for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). Subjects will be treated with pirtobrutinib 200 mg by mouth once daily until disease progression or toxicity. Immune profiling of lymph node (LN) and peripheral blood (PB) will be performed at baseline and on pirtobrutinib. Circulating tumor cells will be analyzed at baseline and on pirtobrutinib. Efficacy and safety will be evaluated.

Objectives:

Primary Objective:

-Evaluate the immune cell composition of LN at baseline and on pirtobrutinib in patients with previously untreated CLL.

Secondary Objectives:

-Evaluate the immune cell composition of PB at baseline and on pirtobrutinib in patients with previously untreated CLL.

Exploratory Objectives:

  • Characterize the transcriptome, immunophenotype, and specificity of immune cells at single-cell resolution at baseline and on pirtobrutinib
  • Evaluate the immunophenotype of circulating immune cells at baseline and on pirtobrutinib
  • Evaluate the cytotoxic and activation potential of T cells at baseline and on pirtobrutinib
  • Characterize the transcriptome of circulating tumor cells at baseline and on pirtobrutinib
  • Evaluate the efficacy of pirtobrutinib in previously untreated CLL
  • Identify preliminary biomarkers of efficacy
  • Evaluate the safety of pirtobrutinib in previously untreated CLL

Endpoints:

Primary Endpoint:

-Immune cell composition estimated by deconvolution of bulk RNA sequencing (RNA-seq) of LN at baseline and on C1D7

Secondary Endpoints:

-Immune cell composition estimated by deconvolution of bulk RNA-seq of PB mononuclear cells (PBMCs) at baseline and on C1D7 and C7D1

Exploratory Endpoints:

  • Single-cell analysis of immune cells from LN and PB at baseline and on C1D7
  • Expression of T-cell differentiation and activation markers by flow cytometric analysis of PBMCs at baseline, on C1D7, and on C7D1
  • Anti-CLL cytotoxicity and activation of autologous T cells obtained at baseline and on C7D1 in response to T-cell engaging bispecific antibodies (bsAb)
  • Bulk RNA-seq of CD19+ PBMCs at baseline, on C1D7, and on C7D1
  • Overall response rate (ORR), progression-free survival (PFS), and minimal residual disease (MRD) status
  • Association between biological parameters and clinical outcomes
  • Incidence and severity of treatment-emergent adverse events (TEAEs)
03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Keywords

  • Pirtobrutinib
  • Chronic Lymphocytic Leukemia (CLL)
  • Immune profiling
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Stated willingness to comply with all study procedures
  2. Age >=18 years
  3. Confirmed diagnosis of CLL or SLL according to International Workshop on CLL (iwCLL) guidelines

    1. Coexpression of CD5, CD19, CD20, and CD23 expression and light-chain restriction; CD23 dim or negative expression is acceptable as long as other parameters are consistent with a diagnosis of CLL.
    2. CLL: clonal B-lymphocytosis >=5,000 cells/mL

    OR

    SLL: lymphadenopathy with the tissue morphology of CLL but that are not leukemic, \<5,000 cells/mL

  4. Active disease requiring treatment according to iwCLL guidelines
  5. characterized by >=1 of the following:

    1. Lymphadenopathy: >=1 lymph node measuring >=1.5 cm in the greatest diameter
    2. Splenomegaly: spleen measuring >13 cm in craniocaudal length
    3. Lymphocytosis: >=5,000 B cells/microL
    4. Bone marrow infiltration: CLL comprising >= 30% of all cells
  6. Previously untreated CLL with >=1 LN amenable to core-needle
  7. Have an (ECOG) performance status of 0-2.
  8. The patient has adequate organ function for all of the following criteria, as defined below:

    • System: Hepatic

      • Laboratory Value: or AST: \<= 3 x the or \<= 5 x ULN with documented liver involvement
      • Laboratory Value: Total : \<= 1.5 x ULN or \<= 3 x ULN with documented liver involvement and/or Gilbert s Disease
    • System: Renal

      --Laboratory Value: Serum creatinine: Calculated >= 30 ml/min according to Cockcroft/Gault Formula: [(140-age) x body weight (kg) x 0.85 (if female)]/ [serum creatinine (mg/dL) x 72]

    • System: Hematologic

      • Laboratory Value: : >= 8 g/dL (>= 80 g/L)
      • Laboratory Value: ANC: >= 0.75 x 10\^9/L
      • Laboratory Value: : >= 50 x 10\^9/L

    Notes:

    Hgb and platelets: independent of transfusions within 7 days of Screening assessment.

    ANC: independent of growth factor support within 7 days of Screening assessment.

    Criteria must be met on C1D1 without transfusion/G-CSF within 7 days of assessment.

    Abbreviations: ALT = alanine aminotransferase; = absolute neutrophil count; AST =aspartate aminotransferase; ULN = upper limit of normal.

  9. Adequate coagulations, defined as (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or international normalized ratio (INR) not greater than 1.5 X ULN.
  10. Willingness of and their partners to observe highly effective methods for the duration of treatment and for 1 month following the last dose of study treatment.
  11. Ability to take oral medication and be willing to adhere to the study drug regimen
  12. Agreement to adhere to Lifestyle Considerations throughout study duration
  13. Able to understand and willing to sign a written document.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Diagnosis of Richter Transformation
  2. Documented CNS involvement
  3. Pregnancy or plan to become pregnant during the study or within 1 month of the last dose of study treatment. must have a negative serum pregnancy test.
  4. Lactation or plan to breastfeed during the study or within 1 week of the last dose of study treatment.
  5. Known active cytomegalovirus (CMV) infections. Unknown or negative status are eligible.
  6. Known active virus (HBV) or virus (HCV) infection based on criteria below:

    1. Patients with positive hepatitis B surface antigen (HBsAg) are excluded.
    2. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require a negative hepatitis B polymerase chain reaction (PCR) evaluation before randomization.
    3. Patients who are HBV DNA PCR positive will be excluded.
  7. Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded.
  8. Patients who have tested positive for (HIV) and have a detectable viral load and/or a \<350 are excluded due to risk of opportunistic infections with both HIV and BTK inhibitors. Eligible patients with HIV must be stable on antiretroviral therapy >=4 weeks prior to study entry. For patients with unknown HIV status, HIV testing will be performed at Screening and result must be negative for enrollment.
  9. active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug. (e.g., gastric bypass surgery, gastrectomy).
  10. Evidence of other clinically significant uncontrolled condition(s) including but not limited to, uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and medical monitor may pose a risk for patient participation. Screening for chronic conditions is not required.
  11. Stroke or intracranial hemorrhage within 6 months of screening
  12. Hypertensive urgency or emergency
  13. Active, clinically significant cardiovascular disease including:

    • Unstable angina or acute coronary syndrome within the past 2 months prior to screening
    • Documentation of by any method of \<= 40% in the 12 months prior to screening
    • Uncontrolled or symptomatic arrhythmias
    • Class 3 or 4 congestive heart failure as defined by Functional Classification
    • Myocardial infarction, unstable angina or acute coronary syndrome within 3 months of screening.
    • Prolongation of the corrected for heart rate (QTcF) > 470 msec. QTcF is calculated using Fridericia s Formula (QTcF): QTcF=QT/(RR\^0.33)

    Correction of suspected drug-induced QTcF prolongation can be attempted at the investigator s discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.

    - Correction for underlying bundle branch block (BBB) allowed.

    Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker

  14. Known allergy/sensitivity to pirtobrutinib or any of the (hydroxypropyl methylcellulose acetate succinate, microcrystalline cellulose, mannitol, sodium starch glycolate, and magnesium stearate.).
  15. History of bleeding diathesis (e.g. von Willebrand disease or hemophlia)
  16. Has received a or live-attenuated vaccine within 28 days before the first dose of pirtobrutinib. Administration of killed vaccines are allowed.
  17. Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist are excluded. Direct oral anticoagulants (DOACs) are allowed.
  18. Diagnosis of primary immunodeficiency or is receiving chronic systemic therapy (in dosing >20 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study medication.
  19. Has active disease that has required systemic treatment in the past 2 years except replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid)
  20. Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.
  21. Active second unless in remission and with >2 years.

    Note: Participants are eligible if they have prostate cancer under active surveillance or observation.

  22. Has not adequately recovered after 4 weeks from major surgery or has ongoing surgical complications.
  23. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  24. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant s participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Pirtobrutinib

    Pirtobrutinib will be administered orally at a dose of 200 mg once daily in 28-day cycles, and participants will continue treatment until disease progression, unacceptable toxicity, or meeting other discontinuation criteria

    Drug: Pirtobrutinib

Interventions

  • Pirtobrutinib will be administered orally at a dose of 200 mg once daily in 28-day cycles

06

What researchers measure

Primary outcomes

  1. Immune cell composition of lymph nodes at baseline and on pirtobrutinib

    Immune cell composition estimated by deconvolution of bulk RNA sequencing (RNA-seq) of lymph node (LN) at baseline and on C1D7

    Time frame: Baseline, Cycle 1 Day 7

Secondary outcomes

  1. Immune cell composition of peripheral blood at baseline and on pirtobrutinib

    Immune cell composition estimated by deconvolution of bulk RNA-seq of peripheral blood mononuclear cells (PBMCs) at baseline and on C1D7 and C7D1

    Time frame: Baseline, Cycle 1 Day 7 and Cycle 7 Day 1

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2030, 46 months after the start.

Of 96 non-industry phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 91. This study's planned 46 months is below that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2026
First posted
Feb 24, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Feb 1, 2030
CompletionEst.
Mar 1, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
3 updates, last Nov 17, 2026
Show all 3 updates
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date
  2. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 22, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07428707
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Mar 11, 2026
Primary completion
Feb 1, 2030 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

NIH Clinical Center Office of Patient Recruitment (OPR)
Contact
ccopr@nih.gov
(800) 411-1222
Laura S Samples, M.D.
Contact
laura.samples@nih.gov
(301) 827-1203
Laura S Samples, M.D.
principal investigator · National Heart, Lung, and Blood Institute (NHLBI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion